Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Psilocybin
Interventions: Psilocybin, Methylphenidate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cystic Fibrosis
Interventions: Cavosonstat, Placebo; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 9 more

Conditions: Adults With Ulcerative Colitis
Interventions: PRIM-DJ2727, Placebos; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypovitaminosis D, Hypovitaminosis
Interventions: Vitamin Arm 1, Vitamin Arm 2, Vitamin Arm 3, Placebo; Dietary Supplement · Other
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Sleep, Body Composition, Strength, Insulin Sensitivity, Energy Expenditure
Interventions: Whey protein, Omega-3 fatty acids; Dietary Supplement
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: Up to 85 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Healthy
Interventions: Wax Ester Marine Oil, Ethyl Ester Marine Oil; Other
Lead sponsor: Calanus; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Aging
Interventions: Rapamycin, Placebo; Drug
Lead sponsor: AgelessRx; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus
Interventions: BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID, BGP-15 200 mg QD, BGP-15 200 mg BID, BGP-15 400 mg QD; Drug
Lead sponsor: N-Gene Research Laboratories, Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Los Angeles, California • Paramount, California • Tustin, California + 17 more

Conditions: Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
Interventions: troriluzole, Placebo; Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 21
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 16 more

Conditions: Covid-19
Interventions: Antroquinonol, Placebo; Drug · Other
Lead sponsor: Golden Biotechnology Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Michigan City, Indiana • Wichita, Kansas • Rockville, Maryland + 2 more

Conditions: Alzheimer's Disease
Interventions: PF-03654746, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Wichita, Kansas

Conditions: Healthy Male
Interventions: GCC-4401, GCC-4401C; Drug
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Moderate to Severe Chronic Plaque Psoriasis
Interventions: Doxercalciferol, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Hot Springs, Arizona • Little Rock, Arkansas + 16 more

Conditions: Congestive Heart Failure
Interventions: Lixivaptan, Placebo; Drug
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 25
States / cities: Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 22 more

Conditions: Hyperinsulinemia, Obesity
Interventions: Metformin HCL, Placebo; Drug
Lead sponsor: Jack Yanovski, M.D.; NIH
Eligibility: 6 Years to 12 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rosacea
Interventions: Doxycycline, Placebo; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Hot Springs, Arkansas • San Diego, California • Evansville, Indiana + 7 more

Conditions: ADHD
Interventions: Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 85 mg; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 31
States / cities: Los Angeles, California • National City, California • Newport Beach, California + 25 more

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: AKBM-3031, Placebo; Dietary Supplement · Other
Lead sponsor: Aker BioMarine Human Ingredients AS; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Beverly Hills, California • Orange, California + 12 more

Conditions: Obstructive Sleep Apnea
Interventions: AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test; Drug · Diagnostic Test
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more

Conditions: Osteoarthritis, Osteoarthritis Thumb Base Joint, Carpometacarpal Osteoarthritis, Thumb
Interventions: CTM, Placebo; Device · Other
Lead sponsor: Indiana Hand to Shoulder Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Hepatitis C
Interventions: Placebo, SCY-635; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: San Francisco, California • Richmond, Virginia

Conditions: Burn
Interventions: Cranberry Extract, Inert Placebo Capsule; Dietary Supplement · Drug
Lead sponsor: Saint Elizabeth Regional Medical Center; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Alzheimer's Disease
Interventions: MK-1942, Donepezil, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Rogers, Arkansas • Hallandale, Florida • Decatur, Georgia + 1 more

Conditions: Alzheimer Disease
Interventions: troriluzole, Placebo oral capsule; Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 44
States / cities: Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 39 more

Search by objective public record fields.

Precision Functional Brain Mapping in Psilocybin

Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor

Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

Evaluating Response to Vitamin D3 and K2 Supplementation in Healthcare Personnel

Nutrition, Body Composition, and Sleep

Study to Evaluate the Acute Bioavailability of EPA and DHA From a DietarySupplement in Healthy Men and Women

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Troriluzole in Adult Participants With Spinocerebellar Ataxia

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis

Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

Metformin to Treat Obesity in Children With Insulin Resistance

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

PRC-063 in Adolescent ADHD

Omega-3 Replacement With Krill Oil in Disease Management of SLE

Crossover Trial of AD109 in Obstructive Sleep Apnea

Efficacy of a Single Injection of CTM for Post-Operative CMC Arthritis

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

Effect of Cranberry Extract on Infections in Burn Patients

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

Study of BHV-4157 in Alzheimer's Disease